NeuroBo Pharmaceuticals: MetaVia's Vanoglipel Shows Promise in Treating Metabolic Dysfunction

MetaVia Inc. Advances Treatment for Metabolic Dysfunction with Vanoglipel

MetaVia Inc. announces significant progress in its clinical development of vanoglipel (DA-1241), a selective G protein-coupled receptor 119 (GPR119) agonist designed to treat metabolic dysfunction-associated steatohepatitis (MASH). The Phase 2a clinical trial, which enrolled 109 participants diagnosed with presumed MASH, evaluates the efficacy of vanoglipel in various dosages, including 50 mg and 100 mg, as well as a combination therapy with a dipeptidyl peptidase-4 inhibitor (DPP4i). Conducted over a 16-week period, the trial reveals promising outcomes presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, showcasing vanoglipel's ability to enhance glucose control, improve liver health, and positively affect plasma lipid profiles.

The trial results indicate that vanoglipel achieves clinically meaningful reductions in HbA1c levels among patients with type 2 diabetes and prediabetes. Furthermore, participants experience notable improvements in liver inflammation, fibrosis, and steatosis, reinforcing the compound's dual activity in enhancing GLP-1 secretion. When combined with DPP4i, the therapeutic effect on metabolic and hepatic pathways is maximized, suggesting a multifaceted approach to managing MASH and its associated metabolic disorders. Hyung Heon Kim, President and CEO of MetaVia, highlights the differentiated mechanism of vanoglipel, underscoring its potential to address the intricate relationship between metabolic dysfunction and liver disease effectively.

As the need for effective therapies in the realm of metabolic dysfunction and liver diseases grows, MetaVia remains optimistic about vanoglipel’s future development. The study demonstrates consistent biochemical, imaging, and metabolic improvements following treatment, positioning vanoglipel as a promising candidate for both monotherapy and combination therapy. The encouraging results pave the way for further exploration into vanoglipel’s capabilities, reinforcing MetaVia's commitment to advancing treatments for complex metabolic conditions.

In related news, the biotechnology sector continues to experience robust growth, with companies actively seeking innovative solutions for chronic diseases. The success of MetaVia’s trial not only highlights the advancements within its product pipeline but also signals a broader trend in the industry towards addressing multifactorial health issues through targeted therapies. As the clinical landscape evolves, developments such as those from MetaVia are pivotal in shaping future treatment paradigms for metabolic disorders.